On September 27, the US Food and Drug Administration (FDA) granted traditional approval to selpercatinib for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
For more information read the FDA announcement.
Posted on 10/7/2024
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
